Haneen Shalabi, D.O.

Haneen Shalabi, D.O.
Assistant Research Physician
Pediatric Oncology Branch

Team Member of:

Nirali N. Shah, M.D., M.H.Sc.

Dr. Shalabi's primary research interests are novel immunotherapy targets for chemo-resistant acute lymphoblastic leukemia. Her clinical focus is the treatment of relapsed/refractory pediatric patients with hematologic malignancies utilizing chimeric antigen receptor (CAR) T cell therapies. Additional areas of interest include neurocognitive effects of immunotherapy in pediatric patients and bone marrow  transplantation for patients with malignant and non-malignant diseases.

Areas of Expertise

1) pediatric leukemia, 2) chimeric antigen receptor (CAR) T cell therapy for pediatric leukemia, 3) immunotherapy for relapsed/refractory hematologic malignancies,
4) cognitive effects post immunotherapy

Contact Info

Haneen Shalabi, D.O.
Center for Cancer Research
National Cancer Institute
Building 10, Room 1W5890
Bethesda, MD 20892
Ph: 240-858-3339
haneen.shalabi@nih.gov

Dr. Shalabi focuses on translation of chimeric antigen receptor therapy to treat high-risk hematologic malignancies in pediatric patients. She works in conjunction with the neurobehavioral team to assess patients receiving immunotherapy for neurocognitive changes.

NIH Scientific Focus Areas:
Clinical Research

Selected Key Publications

  1. Systematic Evaluation of Neurotoxicity in Children and Young Adults Undergoing CD22 Chimeric Antigen Receptor T-Cell Therapy.
    Shalabi H, Wolters PL, Martin S, Toledo-Tamula MA, Roderick MC, Streumph K, Kane E, Yates B, Delbrook C, Mackall CL, Lee DW, Fry TJ, Shah NN.
    Journal of Immunotherapy. 41: 350-358, 2018. [ Journal Article ]
  2. Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma.
    Shalabi H, Kraft IL, Wang HW, Yuan CM, Yates B, Delbrook C, Zimbelman JD, Giller R, Stetler-Stevenson M, Jaffe ES, Lee DW, Shern JF, Fry TJ, Shah NN.
    Hematologica. 103: e215-e218, 2018. [ Journal Article ]
  3. Beyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute Leukemia.
    Shalabi H, Angiolillo A, Fry TJ.
    Frontiers in Pediatrics. 3: 1-12, 2015. [ Journal Article ]
  4. Cell-based Therapies: A New Frontier of Personalized Medicine.
    Shalabi H, Khuu H, Fry TJ, Shah NN.
    In: Novel Designs of Early Phase Trials for Cancer Therapeutics. Elsevier Science 2018. [ Book Chapter ]
  5. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.
    Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, Wolters P, Martin S, Delbrook C, Yates B, Shalabi H, Fountaine TJ, Shern JF, Majzner RG, Stroncek DF, Sabatino M, Feng Y, Dimitrov DS, Zhang L, Nguyen S, Qin H, Dropulic B, Lee DW, Mackall CL.
    Nature Medicine. 24: 20-28, 2018. [ Journal Article ]

Dr. Shalabi received her medical degree in 2010 from Midwestern University, Chicago College of Osteopathic Medicine. In 2013, she completed her pediatric residency in Chicago at Loyola University Medical Center, and then completed her fellowship in pediatric hematology/oncology at Children's National Medical Center in Washington DC in 2016. From 2016-2018, she joined the Pediatric Oncology Branch as an advanced studies fellow with a focus in  pediatric cellular therapies.

Search all
CCR clinical trials